Exelixis Highlights Positive Results for CABOMETYX® (cabozantinib) in Patients with Metastatic...

"Exelixis Highlights Positive Results for CABOMETYX® (cabozantinib) in Patients with Metastatic Papillary Renal Cell Carcinoma in SWOG S1500/PAPMET Study at ASCO GU."

+

021421 Exelixis Highlights Positive Resu

.

Download • 216KB